Zeolitic Imidazolate Frameworks (ZIFs) are one of the potential candidates as highly conducting networks with surface area with a possibility to be used as catalyst support. In the present study, highly active state-of-the-art Pt-NCNTFs catalyst was synthesized by pyrolyzing ZIF-67 along with Pt precursor under flowing Ar-H₂ (90-10 %) gas at 700 °C. XRD analysis indicated the formation of Pt-Co alloy on the surface of the nanostructured catalyst support. The high resolution TEM examination showed the particle size range of 7 to 10 nm. Proton exchange membrane fuel cell performance was evaluated by fabricating membrane electrode assemblies using Nafion-212 electrolyte using H₂/O₂ gases (100 % RH) at various temperatures. The peak power density of 630 mW.cm² was obtained with Pt-NCNTFs cathode catalyst and commercial Pt/C anode catalyst at 70 °C at ambient pressure.

Small and medium office buildings consume a significant parcel of the U.S. building stock energy consumption. Still, owners lack resources and experience to conduct detailed energy audits and retrofit analysis. We present an eight-steps framework for an energy retrofit assessment in small and medium office buildings. Through a bottom-up approach and a web-based retrofit toolkit tested on a case study in Arizona, this methodology was able to save about 50% of the total energy consumed by the case study building, depending on the adopted measures and invested capital. While the case study presented is a deep energy retrofit, the proposed framework is effective in guiding the decision-making process that precedes any energy retrofit, deep or light.

Brazil has had issues in efficiently providing the required amount of electricity to its citizens at a low cost. One of the main causes to the decreasing performance of energy is due to reoccurring droughts that decrease the power generated by hydroelectric facilities. To compensate for the decrease, Brazil brought into use thermal power plants. The power plants being on average 23.7% more expensive than hydroelectric. Wind energy is potentially an alternative source of energy to compensate for the energy decrease during droughts. Brazil has invested in wind farms recently, but, due to issues with the delivery method, only 34% of wind farms are operational. This paper reviews the potential benefit Brazil could receive from investing more resources into developing and operating wind farms. It also proposes that utilization of the best value approach in delivering wind farms could produce operational wind farms quicker and more efficiently than previously experienced.

We described the rapid production of the domain III (DIII) of the envelope (E) protein in plants as a vaccine candidate for West Nile Virus (WNV). Using various combinations of vector modules of a deconstructed viral vector expression system, DIII was produced in three subcellular compartments in leaves of Nicotiana benthamiana by transient expression. DIII expressed at much higher levels when targeted to the endoplasmic reticulum (ER) than that targeted to the chloroplast or the cytosol, with accumulation level up to 73 μg DIII per gram of leaf fresh weight within 4 days after infiltration. Plant ER-derived DIII was soluble and readily purified to > 95% homogeneity without the time-consuming process of denaturing and refolding. Further analysis revealed that plant-produced DIII was processed properly and demonstrated specific binding to an anti-DIII monoclonal antibody that recognizes a conformational epitope. Furthermore, subcutaneous immunization of mice with 5 and 25 μg of purified DIII elicited a potent systemic response. This study provided the proof of principle for rapidly producing immunogenic vaccine candidates against WNV in plants with low cost and scalability.

The increasing world demand for human biologics cannot be met by current production platforms based primarily on mammalian cell culture due to prohibitive cost and limited scalability [1]. Recent progress in plant expression vector development, downstream processing, and glycoengineering has established plants as a superior alternative to biologic production [2–4]. Plants not only offer the traditional advantages of proper eukaryotic protein modification, potential low cost, high scalability, and increased safety but also allow the production of biologics at unprecedented speed to control potential pandemics or with specific glycoforms for better efficacy or safety (biobetters) [5, 6]. The approval of the first plant-made biologic (PMB) by the United States Food and Drug Administration (FDA) for treating Gaucher’s disease heralds a new era for PMBs and sparks new innovations in this field [7, 8].